PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas
NCT ID: NCT04058912
Last Updated: 2019-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2019-05-27
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxidative Stress Gene Polymorphism and Ovarian Reserve Functione
NCT03682341
Ovarian Reserve Following Medical Therapy in Patients With Endometriosis
NCT06799754
Observational Study of Patients Suffering From Endometriosis and Adenomyosis
NCT04862000
Endometrioma Related Reduced Ovarian Reserve
NCT02438735
Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma
NCT01065168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PATİENCE GROUP
1. To be in the range of 18-40 years
2. Patients with an operation indication with \>=5 cm endometrioma
1. Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)
2. Patients who will be followed for IVF cycle due to infertility
PTEN-AKT-FOXO3 Gene Expression
In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
PATİENCE-CONTROL GROUP
1. To be in the range of 18-40 years
2. Patients with operation plan due to non-endometrioma ovarian pathologies
1. Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)
2. Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic
PTEN-AKT-FOXO3 Gene Expression
In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PTEN-AKT-FOXO3 Gene Expression
In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uludag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GÜRKAN UNCU,PROF. MD
: Principal Investigator. Professor, Obstetrician and Gynecologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GURKAN UNCU, Prof
Role: STUDY_DIRECTOR
ULUDAG UNIVERSITY HOSPITAL BURSA TURKEY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uludag University Hospital, Department of Obstetrics and Gynecology
Bursa, Nilufer, Turkey (Türkiye)
Uludag University Hospital, Department of Obstetrics and Gynecology
Bursa, Nilufer, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Govatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study. Hum Reprod. 2014 Feb;29(2):324-36. doi: 10.1093/humrep/det387. Epub 2013 Oct 23.
Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UU-MREC-2019-5/28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.